{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Vulvar+Carcinoma&page=2",
    "query": {
      "condition": "Metastatic Vulvar Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Vulvar+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T08:10:00.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03452332",
      "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cervical Adenocarcinoma",
        "Advanced Vaginal Carcinoma",
        "Advanced Vulvar Carcinoma",
        "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma",
        "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma",
        "Metastatic Cervical Adenocarcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Metastatic Vaginal Adenocarcinoma",
        "Metastatic Vaginal Carcinoma",
        "Metastatic Vulvar Carcinoma",
        "Recurrent Cervical Adenocarcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Recurrent Vaginal Carcinoma",
        "Recurrent Vulvar Carcinoma",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Vaginal Cancer AJCC v8",
        "Stage III Vulvar Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Vulvar Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Vulvar Cancer AJCC v8",
        "Stage IIIC Vulvar Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVA Vulvar Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8",
        "Stage IVB Vulvar Cancer AJCC v8",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Adenocarcinoma",
        "Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2018-07-18",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452332"
    },
    {
      "nct_id": "NCT05686226",
      "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Throat Cancer",
        "Oropharynx Cancer",
        "Anal Cancer",
        "Vulva Cancer",
        "Vaginal Cancer",
        "Penile Cancer",
        "Metastatic Cancer",
        "HPV-Related Malignancy",
        "HPV-Related Carcinoma",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Squamous Cell Carcinoma",
        "HPV-Related Adenocarcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Associated Vaginal Adenocarcinoma",
        "HPV-Related Adenosquamous Carcinoma",
        "HPV-Related Endocervical Adenocarcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma",
        "HPV Positive Rectal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "E7 TCR-T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Christian Hinrichs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-03-07",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05686226"
    },
    {
      "nct_id": "NCT03849469",
      "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Triple Negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced or Metastatic Solid Tumors",
        "Prostate Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Squamous Cell Anal Cancer",
        "Squamous Cell Penile Carcinoma",
        "Squamous Cell Vulvar Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb®22841",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-05-29",
      "completion_date": "2023-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 28,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03849469"
    },
    {
      "nct_id": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acinar Cell Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Adrenal Cortical Carcinoma",
        "Adrenal Gland Pheochromocytoma",
        "Anal Canal Neuroendocrine Carcinoma",
        "Anal Canal Undifferentiated Carcinoma",
        "Angiosarcoma",
        "Apocrine Neoplasm",
        "Appendix Mucinous Adenocarcinoma",
        "Bartholin Gland Transitional Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Bladder Adenocarcinoma",
        "Breast Metaplastic Carcinoma",
        "Cervical Adenocarcinoma",
        "Cholangiocarcinoma",
        "Chordoma",
        "Colorectal Squamous Cell Carcinoma",
        "Desmoid Fibromatosis",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Esophageal Neuroendocrine Carcinoma",
        "Esophageal Undifferentiated Carcinoma",
        "Extrahepatic Bile Duct Carcinoma",
        "Extramammary Paget Disease",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fibromyxoid Tumor",
        "Gallbladder Carcinoma",
        "Gastric Neuroendocrine Carcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastric Undifferentiated Carcinoma",
        "Gastrointestinal Stromal Tumor",
        "Gestational Trophoblastic Tumor",
        "Giant Cell Carcinoma",
        "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",
        "Intestinal Neuroendocrine Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Lung Neuroendocrine Tumor",
        "Lung Sarcomatoid Carcinoma",
        "Major Salivary Gland Carcinoma",
        "Malignant Neoplasm of Unknown Primary",
        "Malignant Odontogenic Neoplasm",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Sex Cord-Stromal Tumor",
        "Metastatic Pituitary Neuroendocrine Tumor",
        "Minimally Invasive Lung Adenocarcinoma",
        "Mixed Mesodermal (Mullerian) Tumor",
        "Mucinous Adenocarcinoma",
        "Mucinous Cystadenocarcinoma",
        "Nasal Cavity Adenocarcinoma",
        "Nasal Cavity Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Nasopharyngeal Low Grade Papillary Adenocarcinoma",
        "Nasopharyngeal Undifferentiated Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Undifferentiated Carcinoma",
        "Ovarian Adenocarcinoma",
        "Ovarian Germ Cell Tumor",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Squamous Cell Carcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Paraganglioma",
        "Paranasal Sinus Adenocarcinoma",
        "Paranasal Sinus Carcinoma",
        "Parathyroid Gland Carcinoma",
        "PEComa",
        "Penile Squamous Cell Carcinoma",
        "Peritoneal Mesothelial Neoplasm",
        "Placental Choriocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Pseudomyxoma Peritonei",
        "Rare Disorder",
        "Scrotal Squamous Cell Carcinoma",
        "Seminal Vesicle Adenocarcinoma",
        "Seminoma",
        "Serous Cystadenocarcinoma",
        "Small Intestinal Adenocarcinoma",
        "Small Intestinal Squamous Cell Carcinoma",
        "Spindle Cell Neoplasm",
        "Teratoma With Somatic-Type Malignancy",
        "Testicular Non-Seminomatous Germ Cell Tumor",
        "Thyroid Gland Carcinoma",
        "Tracheal Carcinoma",
        "Transitional Cell Carcinoma",
        "Ureter Adenocarcinoma",
        "Ureter Squamous Cell Carcinoma",
        "Urethral Adenocarcinoma",
        "Urethral Squamous Cell Carcinoma",
        "Vaginal Adenocarcinoma",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 798,
      "start_date": "2017-01-30",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 1007,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834013"
    },
    {
      "nct_id": "NCT05973487",
      "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Cervical Cancer",
        "Non-small Cell Carcinoma",
        "Melanoma",
        "Ovarian Cancer",
        "Anogenital Cancers",
        "HPV - Anogenital Human Papilloma Virus Infection",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Carcinoma",
        "HPV-Related Squamous Cell Carcinoma",
        "HPV-Related Malignancy",
        "HPV-Related Adenocarcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Adenosquamous Carcinoma",
        "HPV-Associated Vaginal Adenocarcinoma",
        "HPV-Related Endocervical Adenocarcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Verrucous Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma",
        "HPV Positive Rectal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TSC-204-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2024-05-06",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05973487"
    },
    {
      "nct_id": "NCT03896958",
      "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer, All Types",
        "Cancer of Liver",
        "Cancer of Stomach",
        "Cancer of Head and Neck",
        "Cancer of Rectum",
        "Cancer of Kidney",
        "Cancer of Esophagus",
        "Cancer of Colon",
        "Cancer Skin",
        "Cancer of Cervix",
        "Cancer, Metastatic",
        "Cancer of Larynx",
        "Cancer of Neck",
        "Cancer of Lung",
        "Cancer of Brain and Nervous System",
        "Cancer of Vulva, Disseminated",
        "Cancer of Pancreas",
        "Sarcoma",
        "GIST",
        "Small-cell Lung Cancer",
        "Adenocarcinoma Lung",
        "Cancer of Prostate",
        "Cancer, Advanced",
        "Adrenal Cancer",
        "Testicular Cancer",
        "Uterine Cancer",
        "Bronchoalveolar Cell Lung Cancer",
        "Cancer Unknown Primary",
        "Glioblastoma Multiforme",
        "Oligodendroglioma",
        "Breast Cancer",
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Cholangiocarcinoma",
        "Squamous Cell Carcinoma",
        "Transitional Cell Carcinoma",
        "Cancer, Other",
        "Cancer, Anal",
        "Melanoma",
        "Cancer, Bile Duct",
        "Cancer, Bladder",
        "Cancer Cords Vocal",
        "Cancers Cell Neuroendocrine",
        "Cancer Differentiated Poorly",
        "Cancer, Anaplastic Thyroid"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "SpeciCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Month to 99 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2019-03-21",
      "completion_date": "2024-03-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 1,
      "location_summary": "Gainesville, Georgia",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896958"
    },
    {
      "nct_id": "NCT03987555",
      "title": "Paclitaxel Therapeutic Drug Monitoring in Cancer Patients",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumor, Adult",
        "Metastatic Nonsmall Cell Lung Cancer",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Cervical Carcinoma",
        "Metastatic Ovarian Carcinoma",
        "Malignant Uterine Neoplasm",
        "Vulvar Cancer",
        "Invasive Breast Cancer",
        "Metastatic Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Recurrent Breast Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Vulvar Carcinoma",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Vulvar Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Vulvar Cancer AJCC v8",
        "Vulva Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Blood draws",
          "type": "OTHER"
        },
        {
          "name": "QLQ-CIPN20 Survey",
          "type": "OTHER"
        },
        {
          "name": "PR-CTCAE Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-11-11",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03987555"
    },
    {
      "nct_id": "NCT06686043",
      "title": "HPV Vaccine, Imiquimod, and Metformin Combination Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Carcinoma",
        "Vaginal Carcinoma",
        "Vulvar Carcinoma",
        "HPV (Human Papillomavirus)-Associated Carcinoma"
      ],
      "interventions": [
        {
          "name": "HPV vaccine, Imiquimod, and metformin combination therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 85,
      "start_date": "2024-08-23",
      "completion_date": "2028-08-23",
      "has_results": false,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686043"
    },
    {
      "nct_id": "NCT03260023",
      "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Carcinoma",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TG4001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Transgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2017-09-01",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260023"
    },
    {
      "nct_id": "NCT00900302",
      "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-06-10T08:10:00.218Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900302"
    }
  ]
}